Treasurer of the State of North Carolina Has $233.62 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Treasurer of the State of North Carolina lifted its stake in Eli Lilly and Company (NYSE:LLYFree Report) by 0.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 400,775 shares of the company’s stock after buying an additional 3,252 shares during the period. Eli Lilly and Company makes up approximately 1.1% of Treasurer of the State of North Carolina’s investment portfolio, making the stock its 10th biggest position. Treasurer of the State of North Carolina’s holdings in Eli Lilly and Company were worth $233,620,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in LLY. J. W. Coons Advisors LLC grew its holdings in Eli Lilly and Company by 4.0% during the 4th quarter. J. W. Coons Advisors LLC now owns 2,324 shares of the company’s stock worth $1,355,000 after acquiring an additional 90 shares during the last quarter. Solidarity Wealth LLC bought a new position in Eli Lilly and Company in the 4th quarter valued at $5,425,000. Olistico Wealth LLC lifted its holdings in Eli Lilly and Company by 22.6% during the 4th quarter. Olistico Wealth LLC now owns 2,999 shares of the company’s stock worth $1,748,000 after purchasing an additional 552 shares in the last quarter. Legacy Advisors LLC boosted its stake in Eli Lilly and Company by 137.3% during the fourth quarter. Legacy Advisors LLC now owns 4,852 shares of the company’s stock valued at $2,828,000 after buying an additional 2,807 shares during the period. Finally, Elevatus Welath Management lifted its holdings in shares of Eli Lilly and Company by 7.8% during the 4th quarter. Elevatus Welath Management now owns 745 shares of the company’s stock worth $434,000 after acquiring an additional 54 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

LLY has been the subject of a number of analyst reports. JPMorgan Chase & Co. increased their price objective on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research note on Wednesday, May 1st. The Goldman Sachs Group raised their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. Wells Fargo & Company upped their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Citigroup upped their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Finally, Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $769.53.

View Our Latest Stock Analysis on LLY

Insiders Place Their Bets

In related news, major shareholder Lilly Endowment Inc sold 2,052 shares of the company’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total value of $1,660,068.00. Following the completion of the transaction, the insider now owns 98,554,195 shares of the company’s stock, valued at approximately $79,730,343,755. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded up $3.53 during mid-day trading on Thursday, reaching $815.06. 1,968,944 shares of the company’s stock traded hands, compared to its average volume of 2,972,451. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The firm has a market capitalization of $774.64 billion, a PE ratio of 120.24, a price-to-earnings-growth ratio of 1.76 and a beta of 0.37. Eli Lilly and Company has a 12 month low of $422.06 and a 12 month high of $820.60. The firm has a 50 day moving average price of $767.87 and a two-hundred day moving average price of $697.30.

Eli Lilly and Company (NYSE:LLYGet Free Report) last released its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.05. The business had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. Eli Lilly and Company’s revenue for the quarter was up 26.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.62 earnings per share. On average, research analysts forecast that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Shareholders of record on Thursday, May 16th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.64%. The ex-dividend date is Wednesday, May 15th. Eli Lilly and Company’s payout ratio is 76.58%.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Further Reading

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.